FOR PREVIEW ONLY (Print)

Raymond S. Douglas, MD, PhD

West Medical Office Towers
8635 W. Third St., Suite 770W
Los Angeles, CA 90048

Phone:

310-423-8789

Fax:

310-248-8596

Raymond S. Douglas, MD, PhD

  • Ophthalmology

Brow Lift Surgery / Surgeries

Droopy Eyelids

Eye (Ocular) Tumors

Eye Cancers

Eye Reconstructive Surgery / Surgeries

Eye Traumas

Eyelid Cosmetic Revision Surgery / Surgeries (Blepharoplasty)

Eyelid Cosmetic Surgery / Surgeries (Blepharoplasty)

Eyelid Tumors

Facial Cosmetic Fillers (Juvederm, Restylane, Evolence, Radiesse, Sculptra, Perlane)

Facial Plastic Surgery / Surgeries

Facial Reconstructive Surgery / Surgeries

Grave's Disease

Hemifacial Spasm

Lacrimal Surgery / Surgeries

Schwannoma

Thyroid Disorders

Thyroid Eye Diseases

The laboratory of Raymond Douglas, MD, PhD, is interested in thyroid eye disease and facial paralysis, and they have identified key molecular targets for thyroid eye disease. Douglas has just completed the largest clinical trial in the disease for a biologic treatment.

  • Medical School: University of Pennsylvania School of Medicine, 1998
  • Doctorate: University of Pennsylvania School of Medicine, 1998
  • Internship: Presbyterian Hospital, 1999
  • Residency: Scheie Eye Institute, 2002
  • Fellowship: UCLA Stein Eye Institute, 2004
  • Asia-Pacific Academy of Ophthalmology Achievement Award, 2014
  • RPB Lew Wasserman Merit Award, 2011
  • The Endocrine Society's International Award for Excellence in Published Clinical Research, 2011
  • Harbor-UCLA LA BioMed Young Investigator Award for Excellence in Translational Research, 2008
  • Research to Prevent Blindness Career Award, 2007
  • Cosmetic Surgery Foundation, Richard C. Webster Award, 2004
  • ATA Young Investigator Research Career Development Award, 2004
  • Herman Knapp - American Ophthalmological Society Fellowship, 2003
  • UCLA Alumni Association Research Award, 2003
  • Heed Ophthalmic Foundation Fellowship, 2002

Show moreShow less

  • Douglas R, McCoy A, Gupta S. Thyroid Eye Disease. New York:Springer, 2015.
  • Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, Smith TJ, Douglas R. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 2015 Mar;133(3):290-296.
  • Briceño CA, Gupta S, Douglas RS. Advances in the management of thyroid eye disease. Int Ophthalmol Clin. 2013;53(3):93-101.
  • Rootman DB, Kim MJ, Aldave AJ, Douglas R, Hwang C, Goldberg R. Ocular surface, fornix, and eyelid rehabilitation in Boston type I keratoprosthesis patients with mucous membrane disease. Ophthal Plast Reconstr Surg. 2015;31(1):43-49
  • Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014 Jun;34(2):177-185.
  • Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ, Douglas RS. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014 Sep;99(9):E1635-1640.

Show moreShow less

English

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Raymond S. Douglas, MD, PhD